Authors
Experience and expertise
Specialist biotechnology fund managers do not have the option of leaving the sector and returning at a later date. It is their job to navigate this volatile investment environment and preserve the capital in their fund while doing so. This requires experience and expertise. Experience allows the investor to identify where the sector is currently sitting in the valuation cycle and position the portfolio accordingly. Expertise gives the investor the insight that reduces the risk of being heavily invested in companies whose treatments may fail.
Ailsa Craig and Marek Poszepczynski have been working together on the management of International Biotechnology Trust (IBT) since 2013 and took over as joint lead managers in 2021. Over their decade managing the trust, they have developed a rigorous investment process aiming to outperform the index while keeping volatility below that of the index.
Positioning the portfolio according to the valuation cycle
Key to reducing volatility in a portfolio of biotech stocks throughout this investment cycle is to know where the cycle is at any one time and use experience and expertise to benefit from it. To attempt to minimise volatility, managers need to be very conscious of the sector’s investment cycle and position their portfolio to exploit these inevitable shifts in valuations. IBT sees the cycle as follows:
Within the biotech sector there are highly profitable companies with multiple launched drugs and valuations in excess of US$50 billion, companies with a newly launched drug which are not yet making a profit but have high growth expectations and profitability in sight, and at the other end of the spectrum are the more speculative companies in development stage, still working their way through the highly risky process of clinical trials.
Companies that already have established drug sales and are turning a profit are somewhat – like a utility in character. Sales tend to be predictable, based on the number of patients with the condition, and prices are pre-agreed, therefore earnings are visible. Naturally, these companies are usually less volatile during a correction and the resulting period of despair, and tend to be a safer haven for investors trying to weather a storm. Conversely, in a period of established equilibrium and the resulting euphoria, drugs in the early stages of development tend to attract speculative investors, excited by the prospect of new science to address previously untreatable conditions, and so will be particularly buoyant during these periods. However, they will be most exposed to a market downturn when investors will typically desert the companies they deem to be the most risky.
This blog is not providing investment advice and the above does not mean that investors should only buy profitable companies during a correction and only buy early stage companies during periods of tranquillity: there is always value to be found in all pockets of the biotech market as well as the possibility of many other events that may affect a company’s valuation irrespective of market conditions. The underlying drivers of the sector – rising demand from an ageing population and a growing global middle class combined with accelerating innovation in the healthcare industry, - are consistently moving in a positive direction. However, history indicates that during periods of correction and recovery, it is key to tilt the portfolio to be overweight in the segment of the biotech sector that is most likely to outperform. Beyond that, it is important to find the most resilient companies in other segments, to mitigate downside.
Valuation analysis and trading discipline
Understanding biotech valuation is an important tool in managing a biotech portfolio. Having the skill to identify when a stock’s value is overheated and making the difficult decision to sell it, even if it is a favourite stock pick, comes with experience. In a portfolio of stocks where values can move 20-30% or more in a day, it is important to keep on top of the value of every stock, to spot situations where a value needs to be locked in and capitalised through a sale, in anticipation of a correction.
Keeping in mind that the stock can be bought back once the valuation is normalised, is helpful and can mean that stocks are bought and sold multiple times during their time in a portfolio. Conversely, when valuations are depressed, having the expertise to identify the undervalued companies which have a potential catalyst for recovery and sufficient finances to weather the period of despair is crucial.
Volatility management
It would be right to assume that the volatility of the biotech sector is fairly high compared to other sectors. This is further exacerbated by the high risk milestones that are inherent to the drug development process. There are various tools with which a portfolio manager can use, with the aim of cushioning investors from some of this volatility. The most obvious is to hold a diversified portfolio of stocks, spread across all segments of the market, by size, product speciality and development stage. In addition to this, an experienced portfolio manager can choose to trade around impending binary events. IBT’s fund managers aim to reduce their holding from an overweight position in a stock as it approaches one of these binary milestones. Thanks to the inherently optimistic investor mindset, stocks tend to trade up in anticipation of major news. At that point, good fund managers can de-risk the position by selling down to the index weighting or below. If the news that emerges is positive, they can choose to buy more shares as the risk is now much lower, or if it is negative, they avoid the sharp fall that tends to follow. This strategy prioritises capital preservation above seeking maximum rewards regardless of the high risk.
Value for money
Investors in the biotech sector have a choice of ways in which to invest. They could invest in companies directly, but would lose the diversification of a fund and expose them to single company risk. With Consumer Duty coming into force in July 2023, considering value for money is important. Within funds, investors could choose an ETF which would be the cheapest option but would simply give them constant exposure to the entire sector with no quality filter and without access to the expertise or experience of a specialist portfolio manager whose skills may generate superior returns as explained above.
Alternatively, at the most expensive end of the scale they could choose a fund specialising in biotech venture which has the potential to offer a higher return over time, but would typically expose them more to the high risk and volatility in the sector. Identifying a fund which is reasonably priced in fees, gives access to a curated range of investments across the spectrum of the sector, and benefits from the expertise and experience of specialist portfolio managers can offer value for money.
In IBT, investors gain access to investments across the spectrum of the sector with around 8% of the trust in two funds of earlier stage venture assets and the rest in a carefully curated, actively managed, diversified basket of listed stocks. In as sector as specialised and complex as biotech, it is perhaps easier to understand the value in paying extra for a manager with specific stock picking expertise.
By actively exploiting the valuation cyclicality in the market, trading around binary events and holding a diversified portfolio, IBT’s managers seek to use their long experience and their expertise to strive to deliver long term stability from a volatile sector to their investors.
* see page 29 of the latest interim report for a full explanation of IBT’s fee structure which also can include an incentive fee should the fund outperform the benchmark index plus a hurdle.
** as seen on Hargreaves Lansdown website https://www.hl.co.uk/shares/shares-search-results/i/ishares-nasdaq-us-biotechnology-ucits-etf/costs
Important information
This communication is marketing material. The views and opinions contained herein are those of the named author(s) on this page, and may not necessarily represent views expressed or reflected in other Schroders communications, strategies or funds.
This document is intended to be for information purposes only and it is not intended as promotional material in any respect. The material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The material is not intended to provide, and should not be relied on for, accounting, legal or tax advice, or investment recommendations. Information herein is believed to be reliable but Schroder Investment Management Ltd (Schroders) does not warrant its completeness or accuracy.
The data has been sourced by Schroders and should be independently verified before further publication or use. No responsibility can be accepted for error of fact or opinion. This does not exclude or restrict any duty or liability that Schroders has to its customers under the Financial Services and Markets Act 2000 (as amended from time to time) or any other regulatory system. Reliance should not be placed on the views and information in the document when taking individual investment and/or strategic decisions.
Past Performance is not a guide to future performance. The value of investments and the income from them may go down as well as up and investors may not get back the amounts originally invested. Exchange rate changes may cause the value of any overseas investments to rise or fall.
Any sectors, securities, regions or countries shown above are for illustrative purposes only and are not to be considered a recommendation to buy or sell.
The forecasts included should not be relied upon, are not guaranteed and are provided only as at the date of issue. Our forecasts are based on our own assumptions which may change. Forecasts and assumptions may be affected by external economic or other factors.
Issued by Schroder Unit Trusts Limited, 1 London Wall Place, London EC2Y 5AU. Registered Number 4191730 England. Authorised and regulated by the Financial Conduct Authority.
Authors
Topics